A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Clinical trial NCT07276399 · RECRUITING

Trial details

NCT number: NCT07276399
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck

Start date: 2025-12-03
Primary completion: 2029-06-18
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.